The compassionate prescribing framework drawn up by the Director General of the Agence nationale de sécurité du médicament et des produits de santé states in particular, for each medicinal product:
1° The therapeutic indication(s) concerned;
2° The dosage and method of administration;
3° Adverse reactions;
4° The classification of the medicinal product in the categories mentioned in article R. 5121-36, if different from that indicated in the marketing authorisation.
It specifies its period of validity.
It is accompanied by a justification setting out the available data which leads to the presumption that the expected benefits of the medicinal product concerned are greater than the risks incurred in this indication or these indications.
A compassionate prescribing framework may cover several medicinal products and ensure that they are prescribed for the same indication, provided that their mechanism of action is similar.